标题：抗胆碱能药物防治急性肺损伤研究进展

      作者：牟 敏，吴刚明*，孙广运
    (泸州医学院附属医院麻醉科，四川 泸州 646000)

      卷次： 2012年23卷19期

      【摘要】 抗胆碱能药(山莨菪碱、长托宁等)能与M、N胆碱受体结合，对抗乙酰胆碱和其他拟胆碱药物的毒
蕈碱样及烟碱样作用。近年来，随着细胞学和分子学的发展，研究证实抗胆碱药能有效抑制中性粒细胞(PMN)等
效应细胞的活化，减少炎性因子(IL-1等)的释放，减轻多种原因引起的急性肺损伤。本文主要就抗胆碱能药在治
疗急性肺损伤中的研究进展做一综述。

      【关键词】 抗胆碱药 中性粒细胞；炎性因子；急性肺损伤

      【中图分类号】 R563 【文献标识码】 A 【文章编号】 1003—6350（2012）19—120—03<

br>Progress in application of anticholinergics in the prevention and treatment of acute lung injury.
MOU min, WU
Gang-ming, SUN Guang-yun . Department of Anesthesiology, the Affiliated Hospital of Luzhou Medical College, Luzhou
646000, Sichuan, CHINA
【Abstract】 Anticholinergic drug (such as anisodamine, penehyclidine hydrochloride) can combine with M, N
cholinoceptors, and exert antagonistic effects against muscarine as well as nicotine-like action of acetylcholine and oth-
er Cholinomimetics. In the past few years, with the development of cytology and molecule, studies demonstrated that
anticholinergics can actively suppress activation of neutrophilic granulocyte (PMN), reduce the release of inflammato-
ry factor (such as IL-1, IL-6, IL-8), and relieve acute lung injury originated from multi-cause.

      【Key words】 Anticholinergics; Neutrophilic granulocyte; Inflammatory factor; Acute lung injury
基金项目：四川省泸州市科技局资助项目(编号：2011-S-39(1/6))